Name

Neuralink

Legal name

Neuralink Corp.

Website

https://www.neuralink.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Brain-Computer Interface / Implantable Neurotechnology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Brain-computer interfaces
• Neural implants
• Neurotechnology devices
• Implantable medical devices
• Neural signal decoding

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

1. Investigational device trials (pre-commercial): Neuralink is not yet generating commercial revenue: the N1 Implant is an investigational device deployed only under FDA-approved clinical trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME, VOICE). Revenue model is currently nil/reverse-R&D; future revenue is expected to come from hardware sales of the implant, surgical robot procedure fees, and potentially recurring software/service revenue tied to decoder updates.

Go-to-market motion1 record

Core offering

Neuralink develops and manufactures a fully implantable, wireless brain-computer interface platform consisting of the N1 Implant (Link) — a hermetically sealed device with 1,024+ electrodes across 64+ ultra-thin flexible threads — and the R1 surgical robot that inserts those threads into the cortex. Neural signals recorded by the implant are wirelessly transmitted to the Neuralink Application, which decodes them into digital commands enabling cursor, keyboard, and robotic-arm control (Telepathy), with investigational programs extending the platform to speech restoration (VOICE) and artificial vision (Blindsight). The device is currently provided only to participants enrolled in FDA/regulator-approved investigational clinical trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME, VOICE).

Product overview

Neuralink's offering centers on a single integrated product platform for brain-computer interfaces (BCI), comprising the N1 Implant (also branded "Link") as the core implantable device, the R1 Robot that surgically inserts its electrode threads, the N1 Charger that powers it inductively, and the Neuralink Application that decodes neural signals into digital commands. Around this hardware platform sit a portfolio of clinical-trial products and capability modules: the flagship "Telepathy" capability for cursor/keyboard/robotic-arm control, the investigational Blindsight vision-restoration program, and the VOICE speech-restoration study, each backed by named trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME). Complementing the BCI product is the open-source datarepo platform for managing the multimodal neuroscience data generated across Neuralink's vertically integrated R&D, manufacturing, surgery, and clinical operations, and the Neuralink Patient Registry service that recruits and pre-screens participants for trials.

Differentiator

Problem solved

Functional benefit

Brands

• Telepathy: Neuralink's first product — the consumer-facing BCI capability that enables people with paralysis to directly control computers, phones, and robotic limbs using thoughts alone.
• N1 Implant (Link)
• R1 Robot
• Blindsight
• VOICE
• datarepo

Products and services

• N1 Implant (Link) A fully implantable, cosmetically invisible, wireless brain-computer interface the size of a U.S. quarter. It records neural activity through 1,024+ electrodes distributed across 64+ ultra-thin flexible threads (each thinner than a human hair), placed in the cortex by the R1 Robot; signals are processed by custom low-power chips and transmitted wirelessly to the Neuralink Application, which decodes them into digital commands.
• R1 Robot (Surgical Robot) A neurosurgical robot designed to insert the N1 Implant's electrode threads into the cortex. It features a base structure with 3-axis linear motion, a robot head containing 5 camera systems and OCT optics, and a needle thinner than a human hair that grasps, inserts, and releases threads while avoiding blood vessels. Operated under the oversight of board-certified neurosurgeons.
• N1 Charger A compact inductive charger that wirelessly charges the N1 Implant's onboard battery from outside the body, enabling hermetic sealing and cosmetic invisibility without physical connectors.
• Neuralink Application Companion software application that receives wirelessly transmitted neural data from the N1 Implant, decodes the data stream into actions and intents (cursor movements, clicks, text), and runs on external devices such as computers.
• Telepathy Neuralink's first product name for the cursor/keyboard/robotic-arm control capability enabled by the N1 Implant. Telepathy records neural activity from brain regions responsible for the muscles of the hands and arms and translates those signals into digital commands, bypassing damaged neural pathways to enable people with paralysis to directly control computers, phones, and robotic limbs using their thoughts alone.
• Blindsight Neuralink's vision-restoration program and upcoming clinical trial (received FDA Breakthrough Device Designation in September 2024). Designed to restore visual perception for people with severe vision impairment by using a camera on special glasses working in tandem with a brain implant that stimulates the visual cortex, initially providing low-resolution vision.
• VOICE Study (Speech Restoration) Investigational speech-restoration clinical trial (NCT07224256) using the N1 Implant, designed to help people with severe speech impairment from ALS, PLS, spinal cord injury, or stroke output verbal thought as text or directly to speech. ALS patients have used the BCI combined with generative AI voice cloning to produce audible speech that sounds like their original voice.
• PRIME Study Investigational medical device trial (NCT06429735) to evaluate the safety of the N1 Implant and R1 surgical robot, and assess the initial functionality of the BCI for enabling people with quadriplegia from spinal cord injury or ALS to control external devices with their thoughts. Active at Barrow Neurological Institute, University of Miami / The Miami Project to Cure Paralysis, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi.
• CAN-PRIME Study Neuralink's first international clinical trial (NCT06700304), launched in Canada with Health Canada approval at University Health Network (Toronto Western Hospital). Investigates safety and initial BCI functionality in Canadian residents with quadriplegia due to ALS or cervical spinal cord injury.
• GB-PRIME Study Neuralink's first clinical study in Great Britain (launched July 2025), approved by MHRA, HRA/HCRW, and London–Camberwell St Giles REC. Conducted at University College London Hospitals NHS Foundation Trust and The Newcastle upon Tyne Hospitals NHS Foundation Trust; open to residents of Great Britain with limited or no ability to use both hands due to ALS, spinal cord injury, or other neurological conditions.
• CONVOY Study Feasibility trial (NCT06710626) launched November 2024 to extend BCI control using the N1 Implant to an investigational assistive robotic arm (Assistive Robotic Arm/ARA). Cross-enrolls participants from the PRIME Study; conducted at Barrow Neurological Institute with planned expansion to the University of Miami.
• datarepo Open-source platform for managing multimodal data, including real-time neural signals, histopathology images, manufacturing data, surgery video, and 3D volumetric brain scans. The datarepo catalog is a Python library that declaratively defines data sources as code, federates disparate data sources (Delta Lake, Parquet, virtual tables), generates a static web UI, and produces a stateless ROAPI configuration.
• Neuralink Patient Registry Online registry through which individuals with conditions such as quadriplegia, paraplegia, vision loss, hearing loss, aphasia, or amputation can register to learn about current and future Neuralink clinical trials. Open in the United States and Canada; preliminary eligibility assessment only — enrollment in a trial requires separate consent.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability12 records

Feature8 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• BrainCo: Non-invasive EEG-based BCI developer commercializing consumer and education-focused brain-signal products; represents the non-invasive competitive threat and consumer-tier category adjacent to Neuralink's implantable focus.
• Motif Neurotech: Early-stage minimally invasive BCI developer focused on brain-stimulation psychiatric applications; adjacent category participant in the implantable-neuromodulation space alongside Neuralink.
• Science Corp. Founded by Neuralink co-founder Max Hodak; developing BCI and sensory-prosthetic technologies including a Prima retinal prosthesis that has restored sight to >40 blind patients — overlapping in vision-restoration and neural-interface IP.

Direct peers

• Synchron: Direct competitor developing an endovascular (stent-based) brain-computer interface that avoids open brain surgery and has secured FDA IDE approval. Targets similar paralysis/ALS patient populations as Neuralink's Telepathy program.
• Precision Neuroscience: Direct competitor developing a thin-film cortical-surface electrode array (Layer 7) aimed at higher-resolution neural recording with a less invasive surgical footprint than penetrating electrodes.
• Paradromics: Direct competitor building high-bandwidth intracortical BCI technology targeting both medical (communication/motor restoration) and future consumer applications — closely aligned with Neuralink's neural-data-rate roadmap.
• Blackrock Neurotech: Direct competitor with the longest track record in intracortical BCI using Utah-array microelectrodes; competing for the same motor-restoration and communication applications as Neuralink, including FDA Breakthrough-aligned programs.

Broad incumbents

• Boston Scientific: Broad incumbent with significant neuromodulation and DBS franchises plus active BCI-adjacent R&D; competes for hospital-neurosurgery wallet share and is a potential partner or acquirer of BCI IP.
• Abbott: Broad incumbent via its St. Jude / Abbott Neuromodulation business (DBS, SCS, DRG), with established neurosurgical sales channels and FDA-approved implantable neurostimulators that compete for the same hospital budgets and OR slots.
• Medtronic: Established medtech incumbent with deep neuromodulation franchises (DBS, SCS, VNS, PNS) and global neurosurgical commercial infrastructure — the most likely strategic acquirer or competitor as Neuralink moves toward commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/neuralink
• GitHubgithub.com/neuralinkcorp
• YouTubeyoutube.com/@neuralink
• Facebookfacebook.com/Neuralink-105959564083517
• LinkedInlinkedin.com/company/neuralink
• Instagraminstagram.com/neuralink

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds11 records

Investors40 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuralink